Fortis Group Advisors LLC Raises Stock Holdings in Johnson & Johnson $JNJ

Fortis Group Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 304.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 9,570 shares of the company’s stock after buying an additional 7,202 shares during the quarter. Fortis Group Advisors LLC’s holdings in Johnson & Johnson were worth $2,156,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Prevail Innovative Wealth Advisors LLC raised its holdings in Johnson & Johnson by 8.9% during the 4th quarter. Prevail Innovative Wealth Advisors LLC now owns 6,511 shares of the company’s stock valued at $1,347,000 after buying an additional 533 shares during the period. Shakespeare Wealth Management LLC raised its holdings in Johnson & Johnson by 3.4% during the 4th quarter. Shakespeare Wealth Management LLC now owns 3,314 shares of the company’s stock valued at $686,000 after buying an additional 108 shares during the period. Flaharty Asset Management LLC raised its holdings in Johnson & Johnson by 3.0% during the 4th quarter. Flaharty Asset Management LLC now owns 11,470 shares of the company’s stock valued at $2,374,000 after buying an additional 330 shares during the period. CWS Financial Advisors LLC raised its holdings in Johnson & Johnson by 14.0% during the 4th quarter. CWS Financial Advisors LLC now owns 3,963 shares of the company’s stock valued at $820,000 after buying an additional 487 shares during the period. Finally, Fi3 FINANCIAL ADVISORS LLC raised its holdings in Johnson & Johnson by 12.3% during the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 4,473 shares of the company’s stock valued at $926,000 after buying an additional 491 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $229.22 on Thursday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The business’s fifty day simple moving average is $234.43 and its two-hundred day simple moving average is $222.90. Johnson & Johnson has a twelve month low of $149.04 and a twelve month high of $251.71. The firm has a market cap of $551.78 billion, a price-to-earnings ratio of 26.50, a PEG ratio of 2.25 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same quarter last year, the firm posted $2.77 earnings per share. The business’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is currently 60.12%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson launched the next-generation Shockwave C2 Aero Coronary IVL Catheter for calcified coronary artery disease, adding another growth driver in its MedTech/cardiology franchise. Article Title
• Positive Sentiment: J&J said its nipocalimab drug was approved in China, expanding the commercial opportunity for one of its newer immunology therapies. Article Title
• Positive Sentiment: Analyst coverage and recent commentary continue to highlight J&J’s pipeline progress, new drug approvals, and cancer-drug sales as support for stronger long-term growth. Article Title
• Neutral Sentiment: Multiple market commentaries and dividend-stock roundups continue to frame Johnson & Johnson as a defensive, high-quality income stock, which may help limit downside but does not represent a new catalyst. Article Title
• Negative Sentiment: The stock has been trading below its recent highs, suggesting investors may be waiting for clearer evidence that new product launches and approvals will translate into faster earnings growth.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JNJ. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Barclays increased their price target on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Johnson Rice upgraded Johnson & Johnson from a “hold” rating to an “outperform” rating in a research note on Wednesday, May 13th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Finally, Sanford C. Bernstein increased their target price on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.